Angioqueratoma circunscrito. Informe de un caso y revisión de la literatura

ResumenEl angioqueratoma circunscrito es el más raro de los angioqueratomas. Aperece desde el nacimiento o en las primeras dos décadas de la vida y es más común en mujeres. Generalmente está localizado en piernas y un 10% en miembros superiores, es asintomático. Existen diferencias de opinión en cuanto si es una neoplasia o solamente una dilatación de vasos sanguíneos ya existentes. el tratamiento depende del tamaño, profundidad y extención de la lesión. Se debe considerar la extirpación quirúrgica en la medida que sea posible. Se describe el caso de un niño de 10 años con cuadro clínico de angioqueratoma circunscrito tratado con crioterapia, con respuesta parcial de las lesiones.[Ávila M, Vásquez AJ, Pierard EG, Arrese JE, Uribe CJ. Angioqueratoma circunscrito. Informe de un caso y revisión de la literatura. MedUNAB 2002;5(14):118-120].Palabras clave: Angioqueratoma, neoplasia de piel, piel

Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe

Background: HCC is a major cause of cancer death worldwide. Serum biomarkers such as alpha-fetoprotein (AFP), protein induced by vitamin K absence-II, and the Gender, Age, AFP-L3, AFP, Des-gamma-carboxy prothrombin (GALAD) score have been recommended for HCC surveillance. However, inconsistent recommendations in international guidelines limit their clinical utility.Methods: In this multicenter study, over 2000 patient samples were collected in 6 Latin American and 2 European countries. The performance of the GALAD score was validated in cirrhotic cases, and optimized versions were tested for early-stage HCC and prediagnostic HCC detection.Results: The GALAD score could distinguish between HCC and cirrhosis in Latin American patients with an AUC of 0.76, sensitivity of 70%, and specificity of 83% at the conventional cutoff value of −0.63. In a European cohort, GALAD had an AUC of 0.69, sensitivity of 66%, and specificity of 72%. Optimizing the score in the 2 large multicenter cohorts revealed that AFP-L3 contributed minimally to early-stage HCC detection. Thus, we developed a modified GALAD score without AFP-L3, the ASAP (age, sex, AFP, and protein induced by vitamin K absence-II), which showed promise for early-stage HCC detection upon validation. The ASAP score also identified patients with cirrhosis at high risk for advanced-stage HCC up to 15 months before diagnosis (p < 0.0001) and differentiated HCC from hemangiomas, with a specificity of 100% at 71% sensitivity.Conclusion: Our comprehensive analysis of large sample cohorts validates the GALAD score’s utility in Latin American, Spanish, and Dutch patients for early-stage HCC detection. The optimized GALAD without AFP-L3, the ASAP score, is a good alternative and shows greater promise for HCC prediction

Mapping the habitats of a complex circalittoral rocky shelf in the Cantabrian Sea (south Bay of Biscay)

This work focuses on the study of habitats and communities of a high structural complexity area at different levels and scales. This gives us a better understanding of an area from an ecological point of view and at the same time provides us with tools that will facilitate management measures. It was developed in a complex circalittoral rocky platform of the central Cantabrian Sea (Bay of Biscay). The sampling was carried out using a towed photogrammetric vehicle and a rock dredge, which was used for the identification of the species. The first level of the study was the abiotic characterization of the area and the analysis of the communities. These analysis were developed using the unsupervised k-means classification method. For abiotic characterization we used the variables directly associated with the composition and morphology of the ground, such as backscatter, BPI (Bathymetric Position Index), roughness and slope. Depth was also included to discriminate between the circalittoral and bathyal zones. We obtained 5 different classes, which we related to the ground types observed by photogrammetry. In the analysis of the communities, the cluster was based on the sampling units extracted from the images (~10 m), from which 5 assemblages were obtained, providing information on the most abundant species of each class supplied by the abiotic study. The second level was carried out considering a management approach and was based on the modeling of the area at lower resolution, more suitable for the analysis of the habitat-fisheries interactions. Thus, the main habitat-forming species (HFS) of the entire circalittoral area were used to perform delta models based on GAMs (Generalize Additive Models). Obtaining the predictions of presence/absence and combining it with the predictions of densities, we got the zero inflated values density-based model. As all the identified habitats have vulnerable benthic species of a certain size settled on rocky bottoms, they can all be considered to belong to the designation 1170 reefs of the Habitats Directive

Wolbachia in the flesh: symbiont intensities in germ-line and somatic tissues challenge the conventional view of Wolbachia transmission routes

Symbionts can substantially affect the evolution and ecology of their hosts. The investigation of the tissue-specific distribution of symbionts (tissue tropism) can provide important insight into host-symbiont interactions. Among other things, it can help to discern the importance of specific transmission routes and potential phenotypic effects. The intracellular bacterial symbiont Wolbachia has been described as the greatest ever panzootic, due to the wide array of arthropods that it infects. Being primarily vertically transmitted, it is expected that the transmission of Wolbachia would be enhanced by focusing infection in the reproductive tissues. In social insect hosts, this tropism would logically extend to reproductive rather than sterile castes, since the latter constitute a dead-end for vertically transmission. Here, we show that Wolbachia are not focused on reproductive tissues of eusocial insects, and that non-reproductive tissues of queens and workers of the ant Acromyrmex echinatior, harbour substantial infections. In particular, the comparatively high intensities of Wolbachia in the haemolymph, fat body, and faeces, suggest potential for horizontal transmission via parasitoids and the faecal-oral route, or a role for Wolbachia modulating the immune response of this host. It may be that somatic tissues and castes are not the evolutionary dead-end for Wolbachia that is commonly thought

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms “nonalcoholic” and “fatty” were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction–associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction–associated steatotic liver disease, who consume greater amounts of alcohol per week (140–350 g/wk and 210–420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and can improve awareness and patient identification.Fil: Rinella, Mary E.. University of Chicago; Estados UnidosFil: Lazarus, Jeffrey V.. City University of New York; Estados Unidos. Universidad de Barcelona; EspañaFil: Ratziu, Vlad. Sorbonne University; FranciaFil: Francque, Sven M.. Universiteit Antwerp; BélgicaFil: Sanyal, Arun J.. Virginia Commonwealth University; Estados UnidosFil: Kanwal, Fasiha. Baylor College of Medicine; Estados UnidosFil: Romero, Diana. City University of New York; Estados UnidosFil: Abdelmalek, Manal F.. Mayo Clinic; Estados UnidosFil: Anstee, Quentin M.. University of Newcastle; Reino Unido. The Newcastle Upon Tyne Hospitals Nhs Foundation Trust; Reino UnidoFil: Arab, Juan Pablo. Western University; Canadá. Pontificia Universidad Católica de Chile; ChileFil: Arrese, Marco. Escuela de Medicina; Chile. Latin American Association For The Study Of The Liver (aleh) Santiago; ChileFil: Bataller, Ramon. Institut d'Investigacions Biomediques August Pi i Sunyer; EspañaFil: Beuers, Ulrich. University of Amsterdam; Países BajosFil: Boursier, Jerome. Angers University; Estados UnidosFil: Bugianesi, Elisabetta. Università di Torino; ItaliaFil: Byrne, Christopher D.. University of Southampton; Reino UnidoFil: Castro Narro, Graciela E.. Instituto Nacional de la Nutrición Salvador Zubiran; México. Latin American Association for the Study of the Liver; Chile. Fundacion Clinica Medica Sur; MéxicoFil: Chowdhury, Abhijit. Indian Institute Of Liver And Digestive Sciences; India. Universidade Nova de Lisboa; PortugalFil: Cortez Pinto, Helena. Universidade Nova de Lisboa; PortugalFil: Cryer, Donna R.. University of Florida; Estados UnidosFil: Cusi, Kenneth. University of Florida; Estados UnidosFil: El Kassas, Mohamed. Washington University School of Medicine; Estados UnidosFil: Klein, Samuel. University of Washington; Estados UnidosFil: Sookoian, Silvia Cristina. Universidad Maimónides; Argentina. University of Cape Town; Sudáfrica. Pontificia Universidad Católica de Chile; Chile. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Yilmaz, Yusuf. Inova Health System; Estados UnidosFil: Younossi, Zobair. University Of Birmingham; . Universidad de Barcelona; EspañaFil: Hobbs, Ansley. City University of New York; Estados UnidosFil: Villota Rivas, Marcela. University Of Birmingham;Fil: Newsome, Philip N.. University Of Birmingham

Metabolic Factors Limiting Performance in Marathon Runners

Each year in the past three decades has seen hundreds of thousands of runners register to run a major marathon. Of those who attempt to race over the marathon distance of 26 miles and 385 yards (42.195 kilometers), more than two-fifths experience severe and performance-limiting depletion of physiologic carbohydrate reserves (a phenomenon known as ‘hitting the wall’), and thousands drop out before reaching the finish lines (approximately 1–2% of those who start). Analyses of endurance physiology have often either used coarse approximations to suggest that human glycogen reserves are insufficient to fuel a marathon (making ‘hitting the wall’ seem inevitable), or implied that maximal glycogen loading is required in order to complete a marathon without ‘hitting the wall.’ The present computational study demonstrates that the energetic constraints on endurance runners are more subtle, and depend on several physiologic variables including the muscle mass distribution, liver and muscle glycogen densities, and running speed (exercise intensity as a fraction of aerobic capacity) of individual runners, in personalized but nevertheless quantifiable and predictable ways. The analytic approach presented here is used to estimate the distance at which runners will exhaust their glycogen stores as a function of running intensity. In so doing it also provides a basis for guidelines ensuring the safety and optimizing the performance of endurance runners, both by setting personally appropriate paces and by prescribing midrace fueling requirements for avoiding ‘the wall.’ The present analysis also sheds physiologically principled light on important standards in marathon running that until now have remained empirically defined: The qualifying times for the Boston Marathon

Diagnostico del Impacto del Palangre de Fondo en los Hábitats Bentónicos en los LICs de la RN20000

En prens

The Major Yolk Protein Vitellogenin Interferes with the Anti-Plasmodium Response in the Malaria Mosquito Anopheles gambiae

Functional gene analysis in malaria mosquitoes reveals molecules underpinning the trade-off between efficient reproduction and the antiparasitic response

A global research priority agenda to advance public health responses to fatty liver disease

BACKGROUND & AIMS: An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community. METHODS: Nine co-chairs drafted initial research priorities, subsequently reviewed by 40 core authors and debated during a three-day in-person meeting. Following a Delphi methodology, over two rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. The core group revised the draft priorities between rounds. In R2, panellists also ranked the priorities within six domains: epidemiology, models of care, treatment and care, education and awareness, patient and community perspectives, and leadership and public health policy. RESULTS: The consensus-built fatty liver disease research agenda encompasses 28 priorities. The mean percentage of 'agree' responses increased from 78.3 in R1 to 81.1 in R2. Five priorities received unanimous combined agreement ('agree' + 'somewhat agree'); the remaining 23 priorities had >90% combined agreement. While all but one of the priorities exhibited at least a super-majority of agreement (>66.7% 'agree'), 13 priorities had 90% combined agreement. CONCLUSIONS: Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through prevention, identification, treatment, and care. This agenda should catalyse the global health community's efforts to advance and accelerate responses to this widespread and fast-growing public health threat. IMPACT AND IMPLICATIONS: An estimated 38% of adults and 13% of children and adolescents worldwide have fatty liver disease, making it the most prevalent liver disease in history. Despite substantial scientific progress in the past three decades, the burden continues to grow, with an urgent need to advance understanding of how to prevent, manage, and treat the disease. Through a global consensus process, a multidisciplinary group agreed on 28 research priorities covering a broad range of themes, from disease burden, treatment, and health system responses to awareness and policy. The findings have relevance for clinical and non-clinical researchers as well as funders working on fatty liver disease and non-communicable diseases more broadly, setting out a prioritised, ranked research agenda for turning the tide on this fast-growing public health threat

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study

BACKGROUND & AIMS: We performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs without previously reported genetic risk factors. METHODS: We performed a GWAS of 862 persons with DILI and 10,588 population-matched controls. The first set of cases was recruited before May 2009 in Europe (n = 137) and the United States (n = 274). The second set of cases were identified from May 2009 through May 2013 from international collaborative studies performed in Europe, the United States, and South America. For the GWAS, we included only cases with patients of European ancestry associated with a particular drug (but not flucloxacillin or amoxicillin-clavulanate). We used DNA samples from all subjects to analyze HLA genes and single nucleotide polymorphisms. After the discovery analysis was concluded, we validated our findings using data from 283 European patients with diagnosis of DILI associated with various drugs. RESULTS: We associated DILI with rs114577328 (a proxy for A*33:01 a HLA class I allele; odds ratio [OR], 2.7; 95% confidence interval [CI], 1.9-3.8; P = 2.4 × 10-8) and with rs72631567 on chromosome 2 (OR, 2.0; 95% CI, 1.6-2.5; P = 9.7 × 10-9). The association with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related DILI. The variant on chromosome 2 was associated with DILI from a variety of drugs. Further phenotypic analysis indicated that the association between DILI and A*33:01 was significant genome wide for cholestatic and mixed DILI, but not for hepatocellular DILI; the polymorphism on chromosome 2 was associated with cholestatic and mixed DILI as well as hepatocellular DILI. We identified an association between rs28521457 (within the lipopolysaccharide-responsive vesicle trafficking, beach and anchor containing gene) and only hepatocellular DILI (OR, 2.1; 95% CI, 1.6-2.7; P = 4.8 × 10-9). We did not associate any specific drug classes with genetic polymorphisms, except for statin-associated DILI, which was associated with rs116561224 on chromosome 18 (OR, 5.4; 95% CI, 3.0-9.5; P = 7.1 × 10-9). We validated the association between A*33:01 terbinafine- and sertraline-induced DILI. We could not validate the association between DILI and rs72631567, rs28521457, or rs116561224. CONCLUSIONS: In a GWAS of persons of European descent with DILI, we associated HLA-A*33:01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine. We identified polymorphisms that appear to be associated with DILI from statins, as well as 2 non-drug-specific risk factors